肿瘤药学2025，Vol.15Issue(2)：245-251,7.DOI:10.3969/j.issn.2095-1264.2025.02.13
SII/ALB对接受阿片类药物和免疫治疗的NSCLC患者预后的预测价值
Prognostic value of systemic immune inflammation index/albumin ratio for NSCLC patients receiving opioids and immunotherapy
摘要
Abstract
Objective To evaluate the prognostic value of the systemic immune-inflammation index/albumin(SII/ALB)ratio for non-small cell lung carcinoma(NSCLC)patients with cancer pain undergoing treatment with opioids and immune checkpoint inhibitors(ICIs).Methods A retrospective analysis was conducted on 78 NSCLC cancer patients with cancer pain treated with ICIs at Xuzhou Central Hospital from September 1,2021 to September 1,2023.Patient imaging and blood data at 30 d prior to ICI therapy were collected.The cut-off value of SII/ALB was determined using the ROC curve,and the relationship between SII/ALB and clinical data was analyzed using the chi-square test.Kaplan-Meier curves were used to analyze the progression-free survival(PFS)of patients,and univariate and multivariate Cox regression analyses were used to explore the prognostic risk factors of NSCLC patients.Results The area under the ROC curve of SII/ALB before treat-ment was 0.834,and the corresponding cut-off value was 17.79,so the patients were divided into low SII/ALB group(≤17.79)and high SII/ALB group(>17.79).The pretreatment SII/ALB ratio was correlated with the type of lung cancer,ECOG PS score,stage,number of immunotherapy lines,treatment regimen,adverse reactions,and neutrophil indexes(P<0.05).The median progression-free survival(mPFS)of patients in the low SII/ALB group was significantly longer than that in the high SII/ALB group(P<0.001).The objective response rate(ORR)and disease control rate(DCR)in the low SII/ALB group were significantly higher than those in the high SII/ALB group(ORR:35.14%vs.9.76%,P=0.007;DCR:72.97%vs.39.02%,P=0.003).NRS score(HR=0.327,95%CI:0.146～0.736,P=0.007),stage(HR=0.061,95%CI:0.021～0.183,P<0.001)and SII/ALB(HR=0.026,95%CI:0.009～0.075,P<0.001)were independent prognostic risk fac-tors for PFS.Conclusion SII/ALB could be an important biological marker for predicting the prognosis of NSCLC pa-tients treated with opioids and ICIs.关键词
全身免疫炎症指数/血清白蛋白/免疫检查点抑制剂/阿片类药物/癌痛/肺癌Key words
Systemic immune inflammation index/albumin/Immune checkpoint inhibitors/Opioid/Cancer pain/Lung cancer分类
临床医学引用本文复制引用
雷雁,刘勇..SII/ALB对接受阿片类药物和免疫治疗的NSCLC患者预后的预测价值[J].肿瘤药学,2025,15(2):245-251,7.基金项目
徐州医科大学创新团队项目(XYFC2021006) （XYFC2021006）
徐州市卫生健康委员会重点项目(XWKYHT20210589). （XWKYHT20210589）
